Entropy Technologies LP Buys 49,086 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Entropy Technologies LP increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 80.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,727 shares of the biopharmaceutical company’s stock after buying an additional 49,086 shares during the period. Entropy Technologies LP’s holdings in Ultragenyx Pharmaceutical were worth $2,299,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its stake in Ultragenyx Pharmaceutical by 53.4% in the 1st quarter. Renaissance Technologies LLC now owns 561,700 shares of the biopharmaceutical company’s stock worth $11,768,000 after acquiring an additional 195,600 shares in the last quarter. Pale Fire Capital SE increased its position in shares of Ultragenyx Pharmaceutical by 61.7% during the first quarter. Pale Fire Capital SE now owns 16,514 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 6,303 shares during the period. Knott David M Jr raised its stake in shares of Ultragenyx Pharmaceutical by 65.3% during the first quarter. Knott David M Jr now owns 33,069 shares of the biopharmaceutical company’s stock valued at $693,000 after acquiring an additional 13,063 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 66.2% during the first quarter. PNC Financial Services Group Inc. now owns 11,050 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 4,403 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,440 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $26.90 on Monday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $39.89. The business has a fifty day moving average price of $27.45 and a 200 day moving average price of $24.65. The stock has a market capitalization of $2.65 billion, a P/E ratio of -4.40 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. During the same quarter last year, the firm earned ($1.57) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% on a year-over-year basis. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $23.77, for a total value of $110,601.81. Following the sale, the chief financial officer directly owned 105,689 shares in the company, valued at approximately $2,512,227.53. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the sale, the executive vice president owned 94,462 shares in the company, valued at $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 19,319 shares of company stock valued at $476,837. Corporate insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

RARE has been the topic of several research analyst reports. Morgan Stanley increased their price objective on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada upped their target price on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Wedbush cut their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $58.41.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.